# Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.

> **NCT00138983** · PHASE3 · COMPLETED · sponsor: **UMC Utrecht** · enrollment: 200 (—)

## Conditions studied

- Rheumatoid Arthritis
- Polymyalgia Rheumatica
- Giant Cell Arteritis
- Polymyositis
- Wegener's Granulomatosis

## Interventions

- **DRUG:** Alendronate versus alfacalcidol (1-alpha OH vitamin D)

## Key facts

- **NCT ID:** NCT00138983
- **Lead sponsor:** UMC Utrecht
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** —
- **Final completion:** 2003-11
- **Target enrollment:** 200 (—)
- **Last updated:** 2006-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138983, "Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00138983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*